GGrantIndex
Sort

48,018 grants matching immunotherapy

Effects of autoantibodies on synaptic transmission in the retina

$462,428
Catherine W Morgans · Oregon Health & Science University · R01 · FY2014 · EY

Fatty acid signaling in the pancreatic tumor microenvironment

$462,414
Mara H. Sherman · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer

$462,269
Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2025 · CA

Targeting innate immune pathways in breast cancers with chromosomal instability

$462,250
Samuel F Bakhoum · Sloan-Kettering Inst Can Research · P50 · FY2021 · CA

Targeting innate immune pathways in breast cancers with chromosomal instability

$462,250
Samuel F Bakhoum · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA

Understanding the induction of T cell dysfunction in the context of lung cancer

$462,141
Stefani Spranger · Massachusetts Institute Of Technology · R37 · FY2025 · CA

Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.

$462,140
Thomas E. Lloyd · Johns Hopkins University · R01 · FY2023 · AR

Mechanisms of uveal melanoma dormancy and targeted therapy tolerance

$462,127
Andrew E Aplin · Thomas Jefferson University · R01 · FY2024 · CA

MICROFLUIDIC DIAGNOSTICS FOR MONITORING OF BRAF INHIBITOR RESISTANCE IN MELANOMA

$462,107
Hsian-Rong Tseng · University Of California Los Angeles · P01 · FY2014 · CA

Investigating novel targets for topical immunoprevention of keratinocytic skin cancer

$462,092
Sally E Dickinson · University Of Arizona · UG3 · FY2025 · CA

APOBEC3 Proteins in HIV Restriction

$462,062
Reuben S Harris · University Of Minnesota · R37 · FY2016 · AI

Project 2: The Impact of Immunotherapy on Human Vaccination

$462,053
E. John Wherry · Massachusetts General Hospital · U19 · FY2023 · AI

Boosting Antitumor Immunity by Blocking Both Tumor and Adipose DDR1

$462,010
Rong Li · George Washington University · R01 · FY2021 · CA

Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma

$461,996
Abraham Ari Hakimi · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma

$461,978
David M Koelle · University Of Washington · P01 · FY2019 · CA

Deciphering the specificity and molecular mechanisms of regulatory T cells using novel approaches

$461,922
Billur Akkaya · Ohio State University · DP2 · FY2024 · AI

Novel Nanoparticle Respiratory Tract Mucosal Vaccine

$461,920
Frederick D Quinn · University Of Georgia · R61 · FY2024 · AI

DNA damage response and cancer immunity

$461,897
Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

DNA damage response and cancer immunity

$461,897
Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA

Using Nonclassical Estrogen Signaling to Prevent Melanoma

$461,852
Todd W Ridky · University Of Pennsylvania · R01 · FY2019 · CA

Developmental Funds

$461,844
Peter A Jones · University Of Southern California · P30 · FY2013 · CA

Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting

$461,830
Young J. Kim · Vanderbilt University Medical Center · R01 · FY2020 · DE

Computer aided diagnosis of cancer metastases in the brain

$461,828
Xiaoyin Xu · Brigham And Women'S Hospital · R01 · FY2016 · LM

Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy

$461,824
Taha Merghoub · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA

In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.

$461,820
Zelig Eshhar · Tel-Aviv Sourasky Medical Center · R01 · FY2015 · EB